Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus
Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
∙ Each subject must meet the following criteria:
• Patients ≥60 years old on the day of study informed consent
• Patient or legally authorized representative is able and willing to provide written informed consent
• History or evidence of gait impairment with a duration ≥3 months
• Clinical presentation consistent with NPH including two or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with all of the following:
‣ Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans' Index \>0.3) and the absence of severe hippocampal atrophy,
⁃ Pre-procedure spinal tap test or lumbar drain with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%,
⁃ CSF opening pressure ≥8 cmH2O,
⁃ Baseline cognitive evaluation assessed by Montreal Cognitive Assessment (MoCA) test score ≥12
• Patient is willing and able to attend all scheduled visits and comply with study procedures.
• Confirmation of anatomy suitable for the eShunt procedure, as determined by evaluation of pre-procedure imaging (CT and MRI) and approved by an independent anatomical screening committee.